{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:40:43Z","timestamp":1784191243265,"version":"3.55.0"},"reference-count":94,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Pulmonology"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute pulmonary exacerbations\u00a0are complications of cystic fibrosis (CF) and are associated with increased morbidity and mortality. Methicillin\u2010resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA) and <jats:italic>Aspergillus fumigatus<\/jats:italic> are organisms that have been detected in the lungs of CF patients. The focus of this review is to provide an overview of the classes of antimicrobials used for MRSA and allergic bronchopulmonary aspergillosis (ABPA), a hypersensitivity reaction caused by <jats:italic>A. fumigatus<\/jats:italic>. The current anti\u2010MRSA antibiotics and medications for ABPA dosing recommendations are discussed. This article also reviews the findings from the MRSA utilization surveys and the pharmacokinetic and pharmacodynamic differences between CF and non\u2010CF patients. Antimethicillin <jats:italic>S. aureus<\/jats:italic>\u00a0antibiotics include ceftaroline, clindamycin, fluoroquinolone derivatives (ciprofloxacin, levofloxacin), glycopeptide derivatives (telavancin, vancomycin), linezolid, rifampin, sulfamethoxazole\/trimethoprim, and tetracycline derivatives (doxycycline, minocycline, tigecycline). Medications used for ABPA include corticosteroids, amphotericin B, azole antifungals (isavuconazole, itraconazole, posaconazole, voriconazole), and a monoclonal antibody, omalizumab.<\/jats:p>","DOI":"10.1002\/ppul.25353","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T10:08:39Z","timestamp":1614766119000},"page":"1825-1837","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["State of the art in cystic fibrosis pharmacology optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: III. Executive summary"],"prefix":"10.1002","volume":"56","author":[{"given":"Quovadis J.","family":"Epps","sequence":"first","affiliation":[{"name":"Florida Agricultural and Mechanical University College of Pharmacy and Pharmaceutical Sciences  Jacksonville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Epps","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Mayo Clinic  Jacksonville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0977-7257","authenticated-orcid":false,"given":"David C.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, L.S. Skaggs Pharmacy Institute University of Utah College of Pharmacy  Salt Lake City Utah USA"},{"name":"Department of Pharmacy University of Utah Adult Cystic Fibrosis Center  Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6047-306X","authenticated-orcid":false,"given":"Jeffery T.","family":"Zobell","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Intermountain Primary Children's Hospital  Salt Lake City Utah USA"},{"name":"Department of Pharmacy Primary Children's Cystic Fibrosis Center  Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"e_1_2_22_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607183350307"},{"key":"e_1_2_22_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23132"},{"key":"e_1_2_22_4_1","first-page":"CD002204","article-title":"Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis","volume":"11","author":"Elphick HE","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_22_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21240"},{"key":"e_1_2_22_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2004.11.018"},{"key":"e_1_2_22_7_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201405-203AS"},{"key":"e_1_2_22_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2017.04.010"},{"key":"e_1_2_22_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24537"},{"key":"e_1_2_22_10_1","unstructured":"Teflaro. Approved package labeling. Forest Pharmaceuticals Inc.\u00a02016."},{"key":"e_1_2_22_11_1","doi-asserted-by":"publisher","DOI":"10.4065\/74.8.825"},{"key":"e_1_2_22_12_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-2437"},{"key":"e_1_2_22_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.22815"},{"key":"e_1_2_22_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2007.07.010"},{"key":"e_1_2_22_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014567526"},{"key":"e_1_2_22_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2009.06.008"},{"key":"e_1_2_22_17_1","unstructured":"Cipro. Approved package labeling. Bayer HealthCare Pharmaceuticals Inc.2016."},{"key":"e_1_2_22_18_1","unstructured":"Levaquin. Approved package labeling.Janssen Pharmaceuticals Inc.2018."},{"key":"e_1_2_22_19_1","doi-asserted-by":"publisher","DOI":"10.4172\/2153-2435.1000214"},{"key":"e_1_2_22_20_1","unstructured":"Vibativ. Approaved package labeling. Theravance Biopharma Antibiotics Inc.2016."},{"key":"e_1_2_22_21_1","unstructured":"Vancomycin. Approved package labeling. Baxter Healthcare Corporation.2015."},{"key":"e_1_2_22_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir034"},{"key":"e_1_2_22_23_1","unstructured":"https:\/\/wiley.eproofing.in\/Proof.aspx?token=f801f2d026df4c7bb120a44605b09bfc113119275"},{"key":"e_1_2_22_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20966"},{"key":"e_1_2_22_25_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a027011"},{"key":"e_1_2_22_26_1","unstructured":"Rifampin injection. Approved Package Labeling. Mylan Institutional LLC.2018."},{"key":"e_1_2_22_27_1","unstructured":"Rifampin capsule. Approved Package Labeling. Eon Labs Inc.2019."},{"key":"e_1_2_22_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2118-2124.2003"},{"key":"e_1_2_22_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01520-08"},{"key":"e_1_2_22_30_1","unstructured":"Sulfamethoxazole and trimethoprim tablet. Approved Package Labeling. Sun Pharmaceutical Industries Inc.2018."},{"key":"e_1_2_22_31_1","unstructured":"Sulfamethoxazole and trimethoprim injection. Mylan Institutional LLC.2018."},{"key":"e_1_2_22_32_1","doi-asserted-by":"publisher","DOI":"10.4065\/74.7.730"},{"key":"e_1_2_22_33_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198224060-00002"},{"key":"e_1_2_22_34_1","unstructured":"Vibramycin injection approved package labeling. Roerig.2017."},{"key":"e_1_2_22_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/000992287701600110"},{"key":"e_1_2_22_36_1","unstructured":"Tygacil approved package labeling. Wyeth Pharmaceuticals LLC.2018."},{"issue":"2","key":"e_1_2_22_37_1","first-page":"135","article-title":"Ceftaroline fosamil for methicillin\u2010resistant Staphylococcus aureus pulmonary exacerbation in a pediatric cystic fibrosis patient","volume":"19","author":"Molloy L","year":"2014","journal-title":"J Pediatr Pharmacol Ther"},{"key":"e_1_2_22_38_1","unstructured":"Clindamycin phosphate injection. Approved Package Labeling. Akorn Inc.2018."},{"key":"e_1_2_22_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.10.004"},{"key":"e_1_2_22_40_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544020-00005"},{"key":"e_1_2_22_41_1","unstructured":"Vibramycin oral. Approved package labeling. Pfizer Labs.2017."},{"key":"e_1_2_22_42_1","unstructured":"Minocin injection. Approved package labeling. Rempex Pharmaceuticals Inc.2018."},{"key":"e_1_2_22_43_1","unstructured":"UK Cystic Fibrosis Trust Antibiotic Working Group.\u00a0Antibiotic treatment for cystic fibrosis.\u00a02009."},{"key":"e_1_2_22_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2017.10.010"},{"key":"e_1_2_22_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1681"},{"key":"e_1_2_22_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23827"},{"key":"e_1_2_22_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.47.548.366"},{"key":"e_1_2_22_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.1.186"},{"key":"e_1_2_22_49_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-21.2.155"},{"key":"e_1_2_22_50_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp150605"},{"key":"e_1_2_22_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1061"},{"issue":"6","key":"e_1_2_22_52_1","first-page":"406","article-title":"Vancomycin dosing and monitoring in the treatment of cystic fibrosis: results of a national practice survey","volume":"22","author":"Bosso JA","year":"2017","journal-title":"J Pediatr Pharmacol Ther"},{"key":"e_1_2_22_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.281-284.2004"},{"key":"e_1_2_22_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp494"},{"key":"e_1_2_22_55_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-23.2.125"},{"key":"e_1_2_22_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit270"},{"key":"e_1_2_22_57_1","unstructured":"Clindamycin hydrochloride capsule. Approved Package Labeling. Greenstone LLC.2018."},{"key":"e_1_2_22_58_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01797-10"},{"key":"e_1_2_22_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.03.012"},{"key":"e_1_2_22_60_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01308-10"},{"key":"e_1_2_22_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00208-13"},{"key":"e_1_2_22_62_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01392-13"},{"issue":"4","key":"e_1_2_22_63_1","first-page":"e163","article-title":"Linezolid\u2010resistant Staphylococcus aureus in children with cystic fibrosis","volume":"4","author":"Yu D","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"3","key":"e_1_2_22_64_1","first-page":"1878","article-title":"Emergence of cfr\u2010mediated linezolid resistance in a methicillin\u2010resistant Staphylococcus aureus epidemic clone isolated from patients with cystic fibrosis","volume":"60","author":"Antonelli A","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_22_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw108"},{"key":"e_1_2_22_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.11.008"},{"key":"e_1_2_22_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(84)81019-7"},{"key":"e_1_2_22_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000714"},{"key":"e_1_2_22_69_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05710-11"},{"key":"e_1_2_22_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.25080"},{"key":"e_1_2_22_71_1","unstructured":"Solu\u2010Medrol. Approved package labeling. Pharmacia & Upjohn LLC.2020."},{"key":"e_1_2_22_72_1","unstructured":"Amphotericin B injection. Approved package labeling. XGen Pharmaceuticals.2010."},{"key":"e_1_2_22_73_1","unstructured":"Abelect. Approved package labeling. Sigma\u2010Tau Pharmasource Inc.2013."},{"key":"e_1_2_22_74_1","unstructured":"Ambisome. Approved package labeling. Astellas Pharma US Inc.2020."},{"key":"e_1_2_22_75_1","unstructured":"Cresemba. Approved package labeling. Astellas Pharma US Inc.December 2019."},{"key":"e_1_2_22_76_1","unstructured":"Sporanox. Approved package labeling. Pricara Division of Ortho McNeil\u2010Janssen Pharmaceuticals Inc.2001."},{"key":"e_1_2_22_77_1","unstructured":"Noxafil. Approved package labeling. Merck Inc.2015."},{"key":"e_1_2_22_78_1","unstructured":"Vfend. Approved package labeling. Pfizer Inc.2020."},{"key":"e_1_2_22_79_1","unstructured":"Xolair. Approved package labeling. Genentech Inc.2019."},{"key":"e_1_2_22_80_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.6.1937-1938.2001"},{"key":"e_1_2_22_81_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh175"},{"key":"e_1_2_22_82_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645110-00004"},{"key":"e_1_2_22_83_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036077"},{"key":"e_1_2_22_84_1","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myz015"},{"key":"e_1_2_22_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr300"},{"key":"e_1_2_22_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.09.007"},{"key":"e_1_2_22_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.12.006"},{"key":"e_1_2_22_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2009.00384.x"},{"key":"e_1_2_22_89_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00504-10"},{"key":"e_1_2_22_90_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000371"},{"key":"e_1_2_22_91_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200304-505SO"},{"key":"e_1_2_22_92_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008634911114"},{"key":"e_1_2_22_93_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki079"},{"key":"e_1_2_22_94_1","unstructured":"Minocin capsule. Approved package labeling. Patheon Pharmaceuticals.\u00a02010."},{"key":"e_1_2_22_95_1","doi-asserted-by":"publisher","DOI":"10.1086\/376525"}],"container-title":["Pediatric Pulmonology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.25353","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ppul.25353","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.25353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T13:18:55Z","timestamp":1693401535000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ppul.25353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":94,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1002\/ppul.25353"],"URL":"https:\/\/doi.org\/10.1002\/ppul.25353","archive":["Portico"],"relation":{},"ISSN":["8755-6863","1099-0496"],"issn-type":[{"value":"8755-6863","type":"print"},{"value":"1099-0496","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"assertion":[{"value":"2020-12-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}